Search Results - Ruihua Dong

Changes in Early-Phase Clinical Trials in China During 2013-2022: A Review by Jianxiong Zhang, Peng Zhang, Haixue Wang, Ruihua Dong

Connect to this object online.

An open‐label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people by Jingcheng Chen, Jiangshuo Li, Jingxuan Wu, Yuqin Song, Lijun Li, Jianxiong Zhang, Ruihua Dong

Connect to this object online.

Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐d... by Lijun Li, Hongzhi Gao, Kun Lou, Hongmei Luo, Sheng Hao, Jing Yuan, Zeyuan Liu, Ruihua Dong

Connect to this object online.

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1 by Xuewei Cheng, Xia Lv, Hengyan Qu, Dandan Li, Mengmeng Hu, Wenzhi Guo, Guangbo Ge, Ruihua Dong

Connect to this object online.

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder by Ruihua Dong, Hongyun Wang, Dandan Li, Liwei Lang, Frank Gray, Yongzhen Liu, Celine M. Laffont, Malcolm Young, Ji Jiang, Zeyuan Liu, Susan M. Learned

Connect to this object online.

Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects by Jingcheng Chen, Jingxuan Wu, Nini Guo, Yuqin Song, Lijun Li, Bingyan Wang, Jiangshuo Li, Mengyu Hou, Hang Yin, Meijuan Zhang, Yanhong Kong, Xiaofang Wu, Ran Li, Le Wu, Qiannan Gao, Ruihua Dong

Connect to this object online.